Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974910 | 0.84 | MKNK1 (0.44) | KCNA5CYP3A4CYP19A1CYP1A2CYP11B1 | |
| SCHEMBL17963574 | 0.81 | CYP3A4 (0.42) | KCNA5CYP3A4CYP3A5CYP19A1KDM4E | |
| SCHEMBL17963323 | 0.80 | CYP3A4 (0.46) | KCNA5CYP3A4CYP3A5CYP19A1CYP1A2 | |
| SCHEMBL20724247 | 0.80 | CYP3A4 (0.44) | KCNA5CYP3A4CYP3A5CYP19A1KDM4E | |
| SCHEMBL17974909 | 0.79 | NR1H2 (0.44) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17974816 | 0.78 | KCNA5 (0.47) | KCNA5CYP3A4CYP3A5CYP19A1CYP1A2 | |
| SCHEMBL10044245 | 0.74 | CYP19A1 (0.49) | KCNA5CYP3A4CYP3A5CYP19A1CYP1A2 | |
| SCHEMBL13887338 | 0.73 | KCNA5 (0.53) | KCNA5CYP3A4CYP3A5CYP19A1CYP1A2 | |
| SCHEMBL27888098 | 0.73 | CYP19A1 (0.52) | KCNA5CYP3A4CYP3A5CYP19A1CYP1A2 | |
| SCHEMBL17974974 | 0.72 | TSHR (0.52) | CYP3A4KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | KCNA5 4220/4885CYP3A4 4039/4885CYP3A5 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.